logo
Plus   Neg
Share
Email

Merck: FDA Grants Priority Review For Investigational Ebola Vaccine

Merck (MRK) reported that the FDA has granted priority review for the company's Biologics License Application for V920, an investigational Ebola vaccine. The PDUFA, or target action date, is set for March 14, 2020.

In March 2019, the Marketing Authorization Application for V920 was accepted for review by the European Medicines Agency.

"A top priority for us remains achieving registration of V920 and regulatory approval of our German manufacturing site, so that licensed supply can be produced over time to support global public health preparedness and health security objectives," said Paula Annunziato, vice president, Merck Research Laboratories.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Aeronautics and Space Administration or NASA extended its contract with Boeing to build the rocket core stages for its Space Launch System or SLS beyond the first two Artemis missions, and through the next decade. Boeing is the current lead contractor for the core stages of the rockets for the first two missions. The new contract includes the production of ten SLS core stages. The U.S. Food and Drug Administration approved an all-time record total of 1,171 generic drugs in fiscal 2019, breaking its previous record of 971 approvals in fiscal 2018. This year's approvals include 935 full approvals and 236 tentative approvals. A generic drug is a pharmaceutical drug that contains the same chemical substance and performs the same functions as a branded drug. Air Canada has extended its grounding of Boeing's 737 MAX-8 aircraft and removed it from its flying schedule until February 14, 2020. The airline had earlier said its fleet of 24 grounded jetliners will not join its schedules until January 8, 2020. The Canadian flag carrier said the extension is a result of the ongoing regulatory uncertainty about the timing of the aircraft returning to service.
Follow RTT
>